KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Long-Term Investments (2016 - 2025)

Regeneron Pharmaceuticals has reported Long-Term Investments over the past 17 years, most recently at $10.3 billion for Q4 2025.

  • Quarterly results put Long-Term Investments at $10.3 billion for Q4 2025, up 15.29% from a year ago — trailing twelve months through Dec 2025 was $10.3 billion (up 15.29% YoY), and the annual figure for FY2025 was $10.3 billion, up 15.29%.
  • Long-Term Investments for Q4 2025 was $10.3 billion at Regeneron Pharmaceuticals, roughly flat from $10.3 billion in the prior quarter.
  • Over the last five years, Long-Term Investments for REGN hit a ceiling of $10.3 billion in Q3 2025 and a floor of $3.5 billion in Q1 2021.
  • Median Long-Term Investments over the past 5 years was $6.7 billion (2021), compared with a mean of $7.1 billion.
  • Biggest five-year swings in Long-Term Investments: surged 118.08% in 2021 and later fell 18.13% in 2023.
  • Regeneron Pharmaceuticals' Long-Term Investments stood at $6.8 billion in 2021, then decreased by 3.6% to $6.6 billion in 2022, then decreased by 18.13% to $5.4 billion in 2023, then skyrocketed by 64.92% to $8.9 billion in 2024, then increased by 15.29% to $10.3 billion in 2025.
  • The last three reported values for Long-Term Investments were $10.3 billion (Q4 2025), $10.3 billion (Q3 2025), and $10.1 billion (Q2 2025) per Business Quant data.